Scalable cloud-based platform enables Epic Sciences to deliver richer findings to its pharma partners.

San Diego-based Epic Sciences is developing biomarker-driven tests to provide clinically relevant information about how a patient’s cancer changes over time and in response to therapy to guide clinical decisions. From a simple blood draw, Epic Sciences’ no cell left behind® platform technology analyzes approximately six million cells by more than 90 parameters to capture and analyze all possible types of circulating tumor cells (CTCs).